Amy E Bock Selected Research

PF-06410293

6/2022	Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
1/2021	Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
1/2021	Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
1/2018	A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amy E Bock Research Topics

Disease

4	Rheumatoid Arthritis 06/2022 - 01/2018
2	Injection Site Reaction 10/2021 - 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Myocardial Infarction 01/2018
1	Opportunistic Infections (Opportunistic Infection) 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2018

Drug/Important Bio-Agent (IBA)

4	PF-06410293IBA 06/2022 - 01/2018
4	Adalimumab (Humira)FDA Link 06/2022 - 01/2018
4	Biosimilar PharmaceuticalsIBA 06/2022 - 01/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	C-Reactive ProteinIBA 01/2018
1	Biological ProductsIBA 01/2018

Therapy/Procedure

3	Activities of Daily Living (ADL) 06/2022 - 01/2021
1	Therapeutics 01/2021